HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B
© 2020 John Wiley & Sons Ltd..
Nucleos(t)ide analogues (NUC) treatment prevents progression of liver fibrosis in subjects with chronic hepatitis B (CHB). However, risk of hepatocellular carcinoma (HCC) persists despite viral suppression. Specific HBV variants have been associated with adverse outcomes, including HCC; however, the frequency of these variants during the seemingly benign immunotolerant (IT) phase is unknown. Next-generation sequencing and detailed virological characterization on a cohort of treatment-naïve IT subjects were performed to determine the frequency of clinically relevant viral variants. Samples from 97 subjects (genotype B/C 55%/45%, median HBV-DNA 8.5 log10 IU/mL, median HBsAg 4.8 log10 IU/mL, median HBeAg 3.6 log10 PEIU/mL) were analysed. Despite subjects being in the IT phase, clinically relevant HBV variants were common at baseline, particularly in the basal core promoter (BCP, overlaps the hepatitis B X (HBx) gene), precore and PreS regions. BCP/HBx variants were independently associated with lower baseline HBeAg, HBsAg and HBV-DNA titres. Precore variants were independently associated with higher baseline ALT. Increased viral diversity was associated with increased age and lower HBV-DNA, HBsAg and HBeAg levels. Low-level (<5%) drug resistance-associated amino acid substitutions in the HBV reverse transcriptase were detected in 9 (9%) subjects at pre-treatment but were not associated with reduced antiviral activity. Future studies should evaluate whether the detection of HBV variant during IT CHB is predictive of progression to immune clearance and poor prognosis, and whether early initiation of antiviral therapy during IT CHB to prevent the selection of HBV variants is clinically beneficial.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Journal of viral hepatitis - 27(2020), 10 vom: 01. Okt., Seite 1061-1070 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yuen, Lilly [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.08.2021 Date Revised 31.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jvh.13318 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309674298 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309674298 | ||
| 003 | DE-627 | ||
| 005 | 20231225134432.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jvh.13318 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM309674298 | ||
| 035 | |a (NLM)32384174 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yuen, Lilly |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.08.2021 | ||
| 500 | |a Date Revised 31.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 John Wiley & Sons Ltd. | ||
| 520 | |a Nucleos(t)ide analogues (NUC) treatment prevents progression of liver fibrosis in subjects with chronic hepatitis B (CHB). However, risk of hepatocellular carcinoma (HCC) persists despite viral suppression. Specific HBV variants have been associated with adverse outcomes, including HCC; however, the frequency of these variants during the seemingly benign immunotolerant (IT) phase is unknown. Next-generation sequencing and detailed virological characterization on a cohort of treatment-naïve IT subjects were performed to determine the frequency of clinically relevant viral variants. Samples from 97 subjects (genotype B/C 55%/45%, median HBV-DNA 8.5 log10 IU/mL, median HBsAg 4.8 log10 IU/mL, median HBeAg 3.6 log10 PEIU/mL) were analysed. Despite subjects being in the IT phase, clinically relevant HBV variants were common at baseline, particularly in the basal core promoter (BCP, overlaps the hepatitis B X (HBx) gene), precore and PreS regions. BCP/HBx variants were independently associated with lower baseline HBeAg, HBsAg and HBV-DNA titres. Precore variants were independently associated with higher baseline ALT. Increased viral diversity was associated with increased age and lower HBV-DNA, HBsAg and HBeAg levels. Low-level (<5%) drug resistance-associated amino acid substitutions in the HBV reverse transcriptase were detected in 9 (9%) subjects at pre-treatment but were not associated with reduced antiviral activity. Future studies should evaluate whether the detection of HBV variant during IT CHB is predictive of progression to immune clearance and poor prognosis, and whether early initiation of antiviral therapy during IT CHB to prevent the selection of HBV variants is clinically beneficial | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HBV variants | |
| 650 | 4 | |a chronic hepatitis B | |
| 650 | 4 | |a hepatitis B virus | |
| 650 | 4 | |a immune tolerance | |
| 650 | 4 | |a viral diversity | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a DNA, Viral |2 NLM | |
| 650 | 7 | |a Hepatitis B Surface Antigens |2 NLM | |
| 650 | 7 | |a Hepatitis B e Antigens |2 NLM | |
| 700 | 1 | |a Revill, Peter A |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenberg, Gillian |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, Josef |e verfasserin |4 aut | |
| 700 | 1 | |a Littlejohn, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Bayliss, Julianne |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Kathy |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Susanna K |e verfasserin |4 aut | |
| 700 | 1 | |a Gaggar, Anuj |e verfasserin |4 aut | |
| 700 | 1 | |a Kitrinos, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Subramanian, Mani |e verfasserin |4 aut | |
| 700 | 1 | |a Gane, Ed |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Henry L Y |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Bowden, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Locarnini, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, Alexander |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of viral hepatitis |d 1997 |g 27(2020), 10 vom: 01. Okt., Seite 1061-1070 |w (DE-627)NLM074659642 |x 1365-2893 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2020 |g number:10 |g day:01 |g month:10 |g pages:1061-1070 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jvh.13318 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2020 |e 10 |b 01 |c 10 |h 1061-1070 | ||